Aardvark Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Rule 10b5-1 Trading Arrangements
From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the quarter ended September 30, 2025, none of our officers or directors adopted or terminated any such trading arrangements, except as described in the table below:
| Name & Title | Date Adopted | Type of Plan | Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement | Duration |
|---|---|---|---|---|
| Bryan Jones, Ph.D., Chief Operating Officer | September 12, 2025 | Rule 10b5-1 trading arrangement | 75,000 | March 31, 2026* |
*The trading arrangement permits transactions through and including the earlier to occur of (a) the date that all shares subject to the trading arrangement have been sold and (b) the date listed in the table.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.